Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chang Chen, MD^{1,2,#}, Jianying Huang, MD^{1,3,#}, Ping Yin, PhD^{4,#}, Yi Zhang, PhD^{5,6,#}, Zhenshun Cheng, MD⁷, , Jianyuan Wu, PhD^{1,3}, Song Chen, MD⁸, Yongxi Zhang, MD⁹, Bo Chen, PhD^{1,3}, Mengxin Lu, MD⁸, Yongwen Luo, MD⁸, Jingyi Zhang, MD¹⁰, Xinghuan Wang, MD, PhD^{1,3,5,11,*}

Author affiliations:

¹Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

²Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

³Wuhan Leishenshan Hospital, Wuhan, Hubei, 430000, China

⁴Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China

⁵Center for Life Sciences, Peking University, Beijing, 100871, China

⁶Euler Technology, ZGC Life Sciences Park, Beijing, 102200, China

⁷Department of Respiratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

⁸Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

⁹Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China ¹⁰Department of Cardiology, The Third People's Hospital of Hubei Province, Wuhan, Hubei, 430033, China

¹¹Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, China

E-mail addresses: changchen@whu.edu.cn (Chang Chen), znyylcsy@126.com (Jianying Huang), pingyin2000@126.com (Ping Yin), zy@eulertechnology.com (Yi Zhang), chzs1990@163.com (Zhenshun Cheng), wujianyuan@znhospital.com (Jianyuan Wu), song.chen@whu.edu.cn (Song Chen), znact1936@126.com (Yongxi Zhang), znyyssxm@126.com (Bo Chen), mxlu_urology@whu.edu.cn (Mengxin Lu), luoywen@whu.edu.cn (Yongwen Luo), 83351627@qq.com (Jingyi Zhang), wangxinghuan@whu.edu.cn (Xinghuan Wang).

[#]Contributed equally.

*Corresponding author: Dr. Xinghuan Wang, Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China. Tel: +86-27-67813104. E-mail: wangxinghuan@whu.edu.cn

Manuscript word count: Key points 67; Abstract 311; Full text 2996.

Key points

Question: How about the efficacy and safety of favipiravir to treat COVID-19 patients?

Findings: Among patients with confirmed COVID-19, favipiravir, compared to arbidol, did not significantly improve the clinically recovery rate by 7 days. Favipiravir treatment significantly improved time-to-relief for fever and cough, and is associated with manageable adverse effects.

Meaning: For COVID-19 patients, favipiravir is a safe and at least similarly effective option compared to arbidol.

Abstract

Importance: No clinically proven effective antiviral strategy exist for the emerging epidemic Coronavirus Disease 2019 (COVID-19).

Objective: To compare the efficacy and safety of favipiravir and arbidol to treat COVID-19 patients.

Design: Prospective, multicenter, open-label, randomized superiority trial in February,

2020.

Setting: Multicenter study.

Participants: Patients with confirmed COVID-19 admitted to 3 hospitals from Feb.

20, 2020 to Mar. 12, 2020.

Interventions: Conventional therapy + favipiravir or arbidol.

Main Outcomes and Measures:

The primary outcome was clinical recovery rate of day 7. Duration of fever, cough relief latency, and auxiliary oxygen therapy or noninvasive mechanical ventilation rate were the secondary outcomes. The patients with chest CT imaging and laboratory-confirmed COVID-19 infection, aged 18 years or older were randomly assigned to receive favipiravir or arbidol. Safety data were collected for further follow-up for a week.

Results: 120 patients were assigned to favipiravir group (116 assessed) and 120 to arbidol group (120 assessed). In full analysis set (FAS) cohort, clinical recovery rate of day 7 does not significantly differ between the favipiravir group (61.20% (71/116)) and the arbidol group (51.67% (62/120)) (P=0.1396, OR: 1.47). The latency to fever

4

reduction and cough relief in favipiravir group was significantly shorter than that in arbidol group (both P<0.0001). No statistical difference was observed of auxiliary oxygen therapy or noninvasive mechanical ventilation rate (both P>0.05). The most frequently observed favipiravir-associated adverse events were abnormal LFT (10/116, 8.62%, OR: 0.86, P=0.7156), psychiatric symptom reactions (5/116, 4.31%, OR: 5.17, P=0.1149), digestive tract reactions (16/116, 13.79%, OR: 0.97, P=0.6239) and raised serum uric acid (16/116, 13.79%, OR: 5.52, P=0.0014).

Conclusions and Relevance: Among patients with confirmed COVID-19, favipiravir, compared to arbidol, did not significantly improve the clinically recovery rate by 7 days. Favipiravir significantly improved time-to-relief for fever and cough. Antiviral-associated adverse effects associated with favipiravir are mild and manageable.

Trial Registration: This study is registered with Chictr.org.cn, number ChiCTR2000030254.

Introduction

In Dec. 2019, an outbreak of pneumonia caused by SARS-CoV-2 occurred in Wuhan, followed has spread rapidly throughout China. As of Mar. 14, 2020, the WHO reported 146,181 confirmed cases across more than 130 countries.¹ The global mortality rate of COVID-19 is 3.4%,² whereas its mortality rate in Wuhan is 4.3%,³ as the proportion of severe/critical cases in Wuhan is relatively high.

At the moment, there is no specific treatment for COVID-19, so healthcare providers treated the clinical symptoms (fever and breathing difficulties) of patients. Supportive care such as fluid management and anxiliary oxygen therapy can be highly effective for patients. Specifically, no antiviral drugs with RCT proven clinical efficacy for COVID-19 were reported. Clinical studies of some drugs (remdesivir, human interferon alpha-2b, ribavirin, chloroquine, lopinavir and arbidol) were undergoing to test the efficacy and safety for treatment of COVID-19.⁴

SARS-CoV-2 and influenza viruses have a similar disease presentation. Both clinical manifestations are dominated by respiratory symptoms, presenting a wide range of illness from asymptomatic, mild to severe/critical disease with high mortality rate. Importantly, coronavirus and influenza viruses are both RNA virus which depend on RNA-dependent RNA polymerase (RdRp) to replicate. Although no antiviral drugs were proven effective for COVID-19, clinically assessible antiviral options exist for influenza. Arbidol is an antiviral treatment for influenza infection used in Russia and China and has been proposed as a potential treatment for COVID-19.^{5,6} Although arbidol is currently widely used in China for treating COVID-19 based on preliminary

evidences, no RCT is available to show its efficacy for COVID-19. Also, favipiravir, an antiviral drug targeting RdRP,⁷ approved in Japan for influenza, has an IC50 of 0.013-0.48 ug/ml for influenza A, comparing with 2.7-13.8 ug/ml of arbidol.⁸ Hence, we consider favipiravir might serve as a potential candidate to treat COVID-19. We hypothesized that favipiravir would be superior to arbidol in terms of improving clinical recovery rate, and alleviating fever, cough, and breathing difficulties

compared with arbidol. Therefore, we assessed the clinical efficacy and safety of

favipiravir versus arbidol as treatment for COVID-19.

Methods

Study design and participants

We conducted a prospective, multicenter, open-labelled, randomized superiority trial in 240 patients with COVID-19 pneumonia at three hospitals (120 from Zhongnan Hospital of Wuhan University, 88 from Wuhan Leishenshan Hospital, 32 from The Third People's Hospital of Hubei Province). Patients were prospectively enrolled and followed-up from Feb. 20 to Mar. 12, 2020 (Figure 1). According to the proportion of 1:1 between the experimental group (favipiravir) and the control group (arbidol), the randomized open label was produced by professional statistical software SAS9.4. Additional details are in the Trial Protocol (Supplementary file 1), approved by the Institutional Ethics Committee (Nr. 2020040). Written informed consents were obtained from all participants or their authorized representatives.

According to the Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia at that moment,^{9,10} COVID-19 could be diagnosed without a positive nucleic acid test result by: (1) a positive chest CT scan; (2) significant clinical manifestation including fever, cough, breath difficulty and other indications of viral infection of lower respiratory tract; and (3) laboratory results indicating lymphopenia and (optional) leukopenia.

Eligibility criteria was defined as: (1) Aged 18 years or older; (2) Voluntarily signed informed consent; (3) Initial symptoms were within 12 days; (4) Diagnosed as COVID-19 pneumonia.

Patients were excluded if they meet any of following criteria: (1) Allergic to

favipiravir or arbidol; (2) ALT/AST increased to over 6 times of normal upper range, or with Child-Pugh C; (3) Severe/critical patients whose expected survival time <48 hours; (4) Female in pregnancy; (5) HIV infection; (6) Considered unsuitable by researchers.

Procedures

Arbidol is the recommended drug in Chinese guideline.¹⁰ The experimental group (favipiravir) was treated with routine treatment+favipiravir tablets (1600mg each time on the first day, twice a day; 600mg each time from the second day to the end of the experiment, twice a day). The control group (arbidol) was treated with routine therapy+arbidol (200mg each time, 3 times a day, from the first day to the end of the trial). The course of treatment in both groups was 7-10 days. If necessary, the treatment time could be extended to 10 days according to the judgment of researchers.

Definitions

The primary outcome was the clinical recovery rate at 7 days or the end of treatment. Clinical recovery was defined as continuous (>72 hours) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment, with following quantitative criteria: axillary temperature \leq 36.6°C; respiratory frequency \leq 24 times/min; Oxygen saturation \geq 98% without oxygen inhalation; mild or no cough. The armpit temperature, respiratory rate, oxygen saturation without oxygen, oxygen therapy and noninvasive positive pressure ventilation (NPPV) were recorded in daily follow-up. Repeated measurements were made at least twice in each follow-up. The measurements were taken after 15 minutes rest at room temperature (23±2°C). Secondary outcomes included the time from randomization to fever reduction (patients with fever at the time of enrollment), the time from randomization to cough relief (patients with moderate or severe cough at the time of enrollment), the rate of auxiliary oxygen therapy or noninvasive mechanical ventilation during the trial, the all-cause mortality during the trial, the rate of respiratory failure during the trial (defined as $SPO_2 \leq 90\%$ without oxygen inhalation or $PaO_2/FiO_2 < 300$ mmHg, requires oxygen therapy or higher respiratory support).

Blood biochemistry, urinalysis, coagulation function, C-reactive protein and nucleic acid were examined on the third day (D 3 ± 1 day). The above index and CT were examined on the seventh day (D 7 ± 2 day) after taking the drug, and the adverse events and concomitant medication were observed. Classification criteria of moderate, severe and critical COVID-19 patients was described in Trial Protocol.

Statistical Analysis

Sample size estimation: the expected clinical recovery rate at day 7 of the experimental group is 70%, the clinical recovery of the control group is 50%, α =0.025 (single side), β =0.20, power=0.80. According to the distribution ratio of 1:1 between the experimental group and the control group, the statistical sample size is 92 participants in each group. The sample size increased about 20% considering factors such as shedding/elimination. The trial was designed to include 240 participants in the group, including 120 in the experimental group and 120 in the control group.

SAS9.4 software was used for statistical analysis. For the main efficacy indicator/primary outcome (clinical recovery rate after 7 days or the end of treatment),

the comparison between the experimental group and the control group adopts the optimal test. We calculated the bilateral 95% CI of the difference between the clinical recovery rate of the experimental group and the control group. If the lower limit was larger than 0, it was considered the experimental group is superior to the control group. Log rank test was used to compare the recovery latency between the two groups. For the secondary efficacy indicators/secondary outcomes, student's t-test or Wilcoxon rank sum test (if t-test was not applicable) was performed for safety indicators and continuous variables, Wilcoxon rank sum test was used for grade variables. Frequency or composition (%) were used for statistical description of categorial variables, and Chi-square test or Fisher's exact test was used for comparison between groups. For all statistical tests, P<0.05 (bilateral) were considered as statistically significant.

Results

Basic characteristics of patients

A total of 236 patients with COVID-19 were enrolled in FAS (Figure S1-S2), 116 in the favipiravir group and 120 in the arbidol group (Table 1). In the favipiravir group, 59 (50.86%) were males and 57 (49.14%) were females, 87 (75.00%) were <65 years and 29 (25.00%) were \geq 65 years, 36 (31.03%) were with hypertension and 14 (12.07%) with diabetes. In the arbidol group, 51 (42.50%) were males and 69 (57.50%) were females, 79 (65.83%) were <65 years and 41 (34.17%) were \geq 65 years, 30 (25.00%) were with hypertension and 13 (10.83%) with diabetes.

Main signs and symptoms for patients enrolled were fever, fatigue, dry cough, myalgia, dyspnea, expectoration, sore throat, diarrhea, dizziness, insomnia and conjunctivitis, none of which were significantly different between groups. Neither that nucleic acid tests for COVID-19, lymphocyte count, erythrocyte sedimentation rate and C-reactive protein differed between groups. 116 cases in favipiravir group and 119 in arbidol group underwent chest CT, 112 (96.55%) and 114 (95.80%) were diagnosed COVID-19 pneumonia according to the diagnostic criteria (P=0.7635). Overall, no significant difference of basic characteristics of patients between the two groups was observed. However, we noticed a marginally increased ratio of severe to critical patients in the favipiravir group (16+2) compared to arbidol group (8+1) (P=0.0658, Fisher's exact test, OR: 2.25 [0.91-5.98]).

Comparison of clinical recovery rate of day 7 of favipiravir and arbidol in COVID-19 patients

12

The group statistics of primary and secondary outcomes were presented in Table 2 and Table S1. At day 7, 62/120 (51.67%) in the arbidol group and 71/116 (61.21%) patients in the favipiravir group (P=0.1396) were clinically recovered, with the difference of recovery rate between two groups (95% CI) was 0.0954 (-0.0305, 0.2213). Hence, we conclude that favipiravir does not show superior efficacy compared to arbidol in terms of improving the clinical recovery rate at day 7.

Post-hoc test for interaction between treatment and clinical classification showed no interaction between these two factors, both of which contributed to the primary outcome (P=0.017 for treatment, and P<0.001 for clinical classification, with a general linear model). A post-hoc analysis found that for moderate patients with COVID-19, clinical recovery of day 7 was 62/111 (55.86%) in the arbidol group and 70/98 (71.43%) in the favipiravir group (P=0.0199), with the difference of recovery rate between two groups (95% CI) was 0.1557 (0.0271, 0.2843); for severe/critical patients, clinical recovery rate was 0/9 (0%) in the arbidol group and 1/18 (5.56%) in the favipiravir group (P=0.4712), with the difference of recovery rate between two groups (95% CI) was 0.0556 (-0.0503, 0.1614).

Comparison of duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate

Table 3 displayed duration of fever, cough relief time and auxiliary oxygen therapy or noninvasive mechanical ventilation rate between the favipiravir and arbidol groups. During the course of trial observation, for patients in favipiravir group, 71/116 (61.2%) had a fever and 78/116 (67.2%) had a cough; for patients in the arbidol group, 74/120

(61.7%) had a fever and 73/120 (60.8%) had a cough. Whilst the incidence of fever and cough did not differ between two groups at baseline, both the latency to fever reduction and cough relief in the favipiravir group was significantly shorter than that in the arbidol group (P<0.0001).

The incidence of *de novo* auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) was 27/120 (22.50%) in the arbidol group and 21/116 (18.10%) in the favipiravir group (P=0.4015), with the difference of incidence rate between 2 groups (95% CI) was -4.40% (-14.64%, 5.85%). For all cases enrolled in this study, the all-cause mortality was 0. The number of cases of respiratory failure were 4 in arbidol group and 1 in favipiravir group (P=0.3700). Patients with dyspnea was 15/120 (12.5%) in the arbidol group and 13/116 (11.2%) in the favipiravir group (P=0.7588). A post-hoc analysis showed that *de novo* incidences of dyspnea during the course of treatment occurred at 4/116 (3.45%) patients in the favipiravir group and 14/120 (11.67%) patients in the arbidol group (P=0.0174). Hence, we conclude that for secondary outcomes, taking favipiravir significantly shortened the latency to cough relief and reduced fever duration. Favipiravir does not decrease the rate for AOT or NMV, nor does it decrease the overall respiratory failure rate.

Comparison of antiviral-associated adverse effects

During this trial, we detected 37 incidences of antiviral-associated adverse effects (AE) in the favipiravir group and 28 incidences in the arbidol group were observed. All observed AE incidences were level 1. Increased serum uric acid (3 (2.50%) vs 16 (13.79%), P=0.0014) were more common in patients of the favipiravir group than

those in the arbidol group. No statistical difference was observed for the frequency of abnormal LFT (ALT and/or AST were elevated, 12 (10.00%) in the arbidol group vs 10 (8.62%) in the favipiravir group; P=0.7156), psychiatric symptom reactions (dysthesia, 1 (0.83%) vs 5 (4.31%); P=0.1149) and digestive tract reactions (nausea, acid reflux, flatulence,¹¹ 14 (11.67%) vs 16 (13.79%); P=0.6239) (Table 4). Most of these adverse reactions disappeared by the time patients being discharged.

The details of ancillary treatments

Besides famiravir and arbidol, the common ancillary treatments included anti-infection, immunomodulator, nutritional support, symptomatic supportive treatment. Ancillary treatments accompanying the experimental drug differ between moderate and severe/critical patients. Details of drugs use were listed in Table S2 and Figure S3. Most frequently used ancillary treatments were: Moxifloxacin Hydrochloride Tablets (22/18, favipiravir/arbidol group); Cephalosporins (11/5); Antiviral drugs other than the experimental drugs (11/27); Glucocorticoid (5/10); and Human Serum Albumin (4/5). Besides above-mentioned medicine, Chinese herbal medicine was widely used among the patients: Lianhua Qingwen Capsule (a prespecified Chinese herbal medicine recipe for respiratory contagious diseases, 23/30); Qiangli Pipa Lu (a syrup for cough relief, 12/15); and Xuebijing Injection (a prespecified Chinese herbal medicine recipe for anti-inflammation, 8/10). We found that whilst additional antiviral treatments were more frequent in the arbidol group (P=0.0045), it did not positively contribute to the clinical recovery rate at day 7.

Discussion

So far, there are no clinically proven effective antiviral drugs for COVID-19. In China, although arbidol has been officially recommended,¹⁰ observational experiences suggest that its clinical efficacy and safety were not very optimistic. Efficacy of influenza-directed antiviral agents such as favipiravir for treating COVID-19 remain unclear. We conducted a prospective, multicenter, open-labeled, randomized superiority clinical trial and hypothesized that favipiravir would be superior to arbidol in terms of efficacy for moderate symptoms, and would accelerate the clinical recovery of fever, cough, and breathing difficulties (dyspnea) compared with arbidol. Favipiravir treatment did not improve clinical recovery rate of day 7 (61.21%) compared to arbidol group (51.67%). However, it did significantly improve the latency to cough relief and decreased the duration of fever. Interestingly, post-hoc observation showed that a trend of favipiravir being effective to improve clinical recovery rate in moderate COVID-19 patients (70/98, 71.43%) compared to arbidol (62/111, 55.86%) (P=0.0199). This effect diminished for severe/critical COVID-19 patients. Similarly, post-hoc analysis showed that for moderate COVID-19 patients, auxiliary oxygen therapy or noninvasive mechanical ventilation rate was also decreased in favipiravir group (8/98, 8.16%) compared to arbidol group (19/111, 17.12%) with marginal significance (P=0.0541). Finally, in the FAS, post-hoc analysis also showed that favipiravir treatment significantly decreased *de novo* incidences of dyspnea (3.45% vs 11.67%, OR=0.27) during the course of treatment. Whether favipiravir would be only effective for moderate COVID-19 patients is a question

warrant future investigation. Meanwhile, these results suggest a possibility that favipiravir might be effective for halting disease progress into ARDS, shock and multiple organ failure for moderate COVID-19 patients.

The combination of traditional Chinese medicine and antiviral drugs is more common in China, which is due to the traditional medical culture background of the treatment of choice. Also, anti-infection and immune regulation play an important role in the treatment of the COVID-19. Ancillary treatments, such as traditional Chinese medicine, anti-infection and immunomodulatory drugs, were without statistical difference between groups.

Limitations:

(1) For COVID-19, there is no clinically proven effective antiviral drug to serve as the control arm. Although Chinese guideline had recommended several options including recombinant human interferon alpha-2b, ribavirin, chloroquine phosphate, lopinavir and arbidol,¹⁰ no RCT results on these drugs were reported. Clinical studies were currently undergoing to test the efficacy and safety of drugs in the treatment of COVID-19. Despite the known antiviral effect of arbidol for influenza and other virus infections, no clinical trial was done to support its effectiveness for SARS-like virus. Arbidol was widely used by Chinese doctors in the beginning stage of this epidemic of COVID-19 (Jan. 1-30, 2020) based on *in vitro* evidence.¹² Hence, for ethical reasons, we chose arbidol as the positive control drug.

(2) Observation time frame was limited due to the urgency of this matter. For the

same reason, no relapse (including nucleic acid conversion to positive, fever and cough relapse, or pneumonia progress by radiology) tracking were performed for the discharged patients.

(3) In the inclusion criteria, we did not force positive nucleic acid test as a necessity. The accuracy of nucleic acid assay by throat swab sampling was a known issue among clinical practitioners in China. It was estimated that the assay might have at most 30%-50% of sensitivity for patients in early stage of the disease, whilst contact history, clinical manifestations, radiology evidences, and lab results including leukopenia and lymphopenia were confirmatory for these nucleic-acid-negative pneumonia patients. In the Chinese guideline,¹⁰ patients meeting these criteria were considered as confirmed infection. The low sensitivity of PCR-based nucleic acid assay might due to multiple reasons including previous treatment, latency of onset, sampling method, biological specimen characteristics, and the clinical accuracy of specific molecular assay. In this trial, 54/116 patients (46.55%) in favipiravir group and 46/120 (38.33%) in arbidol group were nucleic-acid-positive at day 0. Considering the population incidence of COVID-19 infection at the time of this trial in Wuhan, we consider the probability for mis-identifying patients of pneumonia disease other than COVID-19 into this trial is low.

(4) The eligibility of patients does not prespecify clinical classification as a stratification factor. Ethical concerns arose against completely excluding severe/critical cases from potential beneficial treatment. Additionally, because of the complexity of the disease, progression from moderate to severe/critical is possible.

18

Terminating trial treatment to such patients from the study was considered unacceptable. Post-hoc analysis showed that both treatment and clinical classification contributed significantly to the primary outcome of clinical recovery rate at day 7. Among all participants, there were 18 severe/critical patients in the favipiravir group and 9 severe/critical patients in the arbidol group, which reached a marginal significance (P=0.0531). The difference of clinical classification between groups in the trial had an important impact on its outcome.

Conclusions

Compared to arbidol, favipiravir does not significantly improve clinical recovery rate of day 7. Favipiravir significantly shortened the duration of fever and decreased the latency to cough relief. Antiviral-associated adverse effects of favipiravir is mild and manageable.

Author contributions

Dr. Wang had full access to all of the data in the study and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Study concept and design: C. Chen, Huang, Cheng, Wu, Wang.

Acquisition, analysis, or interpretation of data: C. Chen, Huang, Yin, Yi Zhang,

Wu, Yongxi Zhang.

Drafting of the manuscript: C. Chen, Huang, Yin, Yi Zhang, S. Chen, Lu, Luo, B.

Chen, J. Zhang.

Critical revision of the manuscript for important intellectual content: C. Chen,

Huang, Yi Zhang, Wu, S. Chen, Lu, Luo, J. Zhang, B. Chen.

Statistical analysis: C. Chen, Yin, Yi Zhang, S. Chen.

Obtained funding: Wang.

Administrative, technical, or material support: C. Chen, Huang, Wang.

Study supervision: Huang, Yin, Wang.

Declaration of Interest

All authors have no conflicts of interest to declare.

Data sharing Statement

With the permission of the corresponding author, we can provide participant data,

statistical analysis.

Acknowledgments

This work was supported by the National Key Research and Development Program of China (2020YFC0844400).

We would like to acknowledge the support of China National Center for Biotechnology Development, Science and Technology Department of Hubei Province. We thank the excellent technical assistance of Dr. Xiuli Zhao (Beijing Tongren Hospital, Capital Medical University, Beijing, China). We also thank the help from the rescue medical teams for Hubei province (Tianjin medical team, Liaoning medical team, Guangdong Province Traditional Chinese Medical Hospital, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, and Puren Hospital of Wuhan University of Science and Technology).

Role of the Funder/Sponsors

The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References

- 1. WHO. Coronavirus disease 2019 (COVID-19) Situation Report. 2020; https://www.who.int/.
- 2. Roser M, Ritchie H, Ortiz-Ospina E. Coronavirus Disease (COVID-19)-Statistics and Research. 2020; https://ourworldindata.org/coronavirus.
- 3. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020; published online Feb 07. doi: 10.1001/jama.2020.1585.
- 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020; published online Mar 11. doi: 10.1016/S0140-6736(20)30566-3.
- 5. Hulseberg CE, Feneant L, Szymanska-de Wijs KM, et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. *J Virol.* 2019;93(8).
- 6. Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. *Arch Virol.* 2007;152(8):1447-1455.
- 7. Goldhill DH, Te Velthuis AJW, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. *Proc Natl Acad Sci U S A*. 2018;115(45):11613-11618.
- 8. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. *Antimicrob Agents Chemother*. 2002;46(4):977-981.
- 9. Chinese diagnosis and treatment plan of COVID-19 patients (The fifth edition). 2020; http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b891 2d4440.shtml.
- 10. Chinese diagnosis and treatment plan of COVID-19 patients (The sixth edition). 2020; http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8 aefc2.shtml.
- 11. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. *bioRxiv*. 2020;2020.01.30.927806; doi: https://doi.org/10.1101/2020.01.30.927806.
- 12. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020; published online Jan 29. doi: 10.1056/NEJMoa2001316.

Figure legend

Figure 1. Flow Diagram of the Study.

Variables	Favipiravir group	Arbidol group	P value	
variabits	(N = 116)	(N = 120)	r value	
Gender, n (%)			0.2473	
Female	57 (49.14)	69 (57.50)		
Male	59 (50.86)	51 (42.50)		
Age (years), n (%)			0.1232	
< 65	87 (75.00)	79 (65.83)		
\geq 65	29 (25.00)	41 (34.17)		
Clinical Classification, n (%)			0.1540	
Moderate	98 (84.48)	111 (92.50)		
Severe	16 (13.79)	8 (6.67)		
Critical	2 (1.72)	1 (0.83)		
Hypertension, n (%)	36 (31.03)	30 (25.00)	0.3018	
Diabetes, n (%)	14 (12.07)	13 (10.83)	0.7656	
Insomnia, n (%)	16 (13.79)	29 (24.17)	0.0426	
Conjunctivitis, n (%)	6 (5.17)	7 (5.83)	1.0000*	
Signs and symptoms, n (%)				
Fever	64 (55.17)	61 (50.83)	0.5911	
Fatigue	40 (34.48)	27 (22.50)	0.0579	
Dry cough	70 (60.34)	64 (53.33)	0.3393	
Myalgia	2 (1.72)	3 (2.50)	1.0000*	
Dyspnoea	9 (7.76)	4 (3.33)	0.2285	
Expectoration	13 (11.21)	11 (9.17)	0.7619	
Sore throat	9 (7.76)	17 (14.17)	0.1726	
Diarrhoea	22 (18.97)	15 (12.50)	0.2354	
Dizziness	1 (0.86)	5 (4.17)	0.2306	
Laboratory findings				
Nucleic acid tests, n (%)	N = 116	N = 120	0.4202	
Positive	54 (46.55)	46 (38.33)		
Suspected	6 (5.17)	6 (5.00)		
Lymphocyte count, ×10 ⁹ /L	N = 116	N = 120	0.5316	
Mean (SD)	0.95 (0.25)	0.97 (0.34)		
Min-Max	0.54-2.14	0.36-2.21		
Erythrocyte sedimentation rate (ESR)	N = 114	N = 120	0.9498	
Mean (SD)	17.24 (14.34)	17.34 (10.76)		
Min-Max	2.00-96.00	2.00-61.00		
C-reactive protein (CRP)	N = 116	N = 118	0.4796	
Mean (SD)	10.91 (21.55)	9.19 (14.92)		
Min-Max	0.50-212.60	0.50-111.90		
Chest CT (N = 235 with data), n (%)	116	119	0.7635	

Table 1. Basic characteristics of the participants.

COVID-19 pneumonia

112 (96.55)

114 (95.80)

^{*}T-test was performed for continuous variables, frequency or composition (%) were used for statistical description of classification indexes, and Chi-square test or Fisher's exact test was used for comparison between groups.

Variables	Favipiravir group	Arbidol group	Rate ratio (95% CI)	P value
Total patients	(N = 116)	(N = 120)		0.1396
Recovered, n (%)	71 (61.21)	62 (51.67)	0.0954 (-0.0305, 0.2213)	
Moderate patients	(N = 98)	(N = 111)		
Recovered, n (%)	70 (71.43)	62 (55.86)	0.1557 (0.0271, 0.2843)	0.0199
Severe or critical patients	(N = 18)	(N = 9)		
Recovered, n (%)	1 (5.56)	0 (0.00)	0.0556 (-0.0503, 0.1614)	0.4712
Patients with hypertension and/or diabetes	(N = 42)	(N = 35)		
Recovered, n (%)	23 (54.76)	18 (51.43)	0.0333 (-0.1904, 0.2571)	0.7704

Table 2. Comparison of clinical recovery rate of day 7.

Variables	Duration of fever		Cough relief time		
	Favipiravir group	Arbidol group	Favipiravir group	Arbidol grou	
Total patients	(N = 71)	(N = 74)	(N = 78)	(N = 73)	
Day 1	15 (21.13)	2 (2.70)	1 (1.28)	3 (4.11)	
Day 2	23 (32.39)	8 (10.81)	2 (2.56)	1 (1.37)	
Day 3	19 (26.76)	18 (24.32)	23 (29.49)	7 (9.59)	
Day 4	10 (14.08)	15 (20.27)	20 (25.64) 11 (
Day 5	1 (1.41)	16 (21.62)	10 (12.82) 1		
Day 6	-	5 (6.76)	10 (12.82)	10 (13.70)	
Day 7	-	3 (4.05)	3 (3.85)	3 (4.11)	
Day 8	-	-	7 (8.97)	6 (8.22)	
Day 9	-	-	1 (1.28)	3 (4.11)	
Censored	-	-	1 (1.28)	17 (23.29)	
Log-rank P value	< 0.0	001	< 0.0001		
	Other s	secondary outcomes			
AOT or NMV [*]	Favipiravir group	Arbidol group	Rate ratio (95% CI)	P value	
Total patients	N = 116	N = 120			
With auxiliary, n (%)	21 (18.10)	27 (22.50)	-0.0440 (-0.1464, -0.0585)	0.4015	
Patients with hypertension and/or diabetes	N = 42	N = 35			
With auxiliary, n (%)	9 (21.43)	10 (28.57)	-0.0714 (-0.2658, 0.1230)	0.4691	
All-cause mortality	0 (0.00)	0 (0.00)	/	/	
Dyspnea after taking medicine, n (%)	4 (3.45)	14 (11.67)	/	0.0174	
Respiratory failure, n (%)	1 (0.86)	4 (3.33)	/	0.3700^{*}	

Table 3. Comparison of du	ation of fever, cough relief time a	and other secondary outcomes.
---------------------------	-------------------------------------	-------------------------------

*Fisher's exact test was used for comparison between groups.

Adverse effects	Favipiravir group (N = 116)		Arbidol group (N = 120)		D l
	Frequency	Cases, n (%)	Frequency	Cases, n (%)	P value
Total	43	37 (31.90)	33	28 (23.33)	0.1410
Abnormal LFT	10	10 (8.62)	12	12 (10.00)	0.7156
Raised serum uric acid	16	16 (13.79)	3	3 (2.50)	0.0014
Psychiatric symptom reactions	5	5 (4.31)	1	1 (0.83)	0.1149*
Digestive tract reactions	16	16 (13.79)	17	14 (11.67)	0.6239

Table 4. Comparison of antiviral-associated adverse effects.

^{*}Fisher's exact test was used for comparison between groups.

